In a study published in BMJ Open included 28 randomized controlled trials, with 5,446 adult participants of all age groups, it was seen that zinc lowered (28 percent) risk of contracting symptoms consistent with the common cold and contracting a flu-like illness (68 percent). However, the protective effects of zinc were insignificant (4 percent lower risk) when participants were purposely infected with human rhinovirus.
Further, zinc also shortened the duration of symptoms by around two days and reduced day 3 symptomatic severity around the peak of illness, but the reduction in overall symptom severity was insignificant.
While there was an increased risk of non-serious adverse events that may limit tolerability for some (such as nausea or mouth and nasal irritation), the risk of serious adverse events (such as copper deficiency from oral zinc and loss of smell from zinc nasal sprays and gels) was low.
However, "we cannot assume the results apply to Covid-19", said lead author Jennifer Hunter, Associate Professor at Western Sydney University's NICM Health Research Institute. "It is commonly thought that zinc's role in preventing and treating infections is only for people who are zinc deficient; our findings really challenge this notion," she added.
The team also highlighted in their findings the challenges around the variability of zinc formulations and doses, and their mechanisms of action. "At the moment there just isn't enough research to say whether a zinc nasal spray, versus a nasal gel, versus a lozenge, versus oral zinc is any better or worse than the others. Most of the trials used zinc gluconate or zinc acetate formulations, but that doesn't mean that other zinc compounds are less effective," Hunter said.
Despite these uncertainties, Hunter said zinc products are widely available, affordable, and generally safe, including the short-term use of high-dose zinc lozenges and capsules that was used in many of the trials.
(IANS)
Also Read: Zinc: Requirements, Deficiency, Benefits And Food Sources
